Clinical Trials on Malignant Melanoma

Total 7184 results

Immunocore Ltd

Completed

Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma

Malignant Melanoma

United Kingdom, United States
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Hoffmann-La Roche

Completed

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Malignant Melanoma

China
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Malignant Melanoma

Italy
Hadassah Medical Organization

Unknown

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Malignant Melanoma

Israel
Merck Sharp & Dohme LLC

Terminated

A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

Malignant Melanoma
Hoffmann-La Roche

Completed

An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)

Malignant Melanoma

Italy, United Kingdom, Belgium, Poland, Netherlands, Germany, Austria, Czechia, Ireland, Sweden
Celgene
NYU Langone Health; Syneos Health; Celerion; ApoCell, Inc.

Completed

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Malignant Melanoma

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
H. Lee Moffitt Cancer Center and Research Institute
National Gene Vector Laboratory

Completed

Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma

Malignant Melanoma

United States
Genentech, Inc.

Completed

A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma

Malignant Melanoma

United States, Australia
Hoffmann-La Roche

Terminated

BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations

Malignant Melanoma

United States, France, Australia, United Kingdom, Italy, Spain, Germany, Israel, Poland, Slovakia
Oslo University Hospital

Completed

Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

Malignant Melanoma

Norway
James Graham Brown Cancer Center
University of Louisville

Completed

Phase II Trial of Ontak With Metastatic Melanoma

Malignant Melanoma

United States
Yonsei University

Completed

A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy

Malignant Melanoma

Korea, Republic of
SciBase AB

Completed

SciBase International Melanoma Pivotal Study

Malignant Melanoma

United States, Sweden
Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
AmpliMed Corporation

Completed

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Malignant Melanoma

United States
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center

Completed

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Malignant Melanoma

United States
NeoPlas Innovation

Withdrawn

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

Melanoma | Malignant Melanoma

United States
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
Northern California Melanoma Center
Bayer; Melanoma Research Institute

Completed

GM-CSF as Adjuvant Therapy of Melanoma

Malignant Melanoma

United States
Titan Pharmaceuticals

Terminated

A Pilot Study of Pivanex in Patients With Malignant Melanoma

Malignant Melanoma

United States
CNAO National Center of Oncological Hadrontherapy

Recruiting

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract (CYCLE)

Gynecologic Cancer | Malignant Melanoma

Italy
The Netherlands Cancer Institute
4SC

Active, not recruiting

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (DONIMI)

Malignant Melanoma Stage III

Netherlands
University Hospital Tuebingen

Unknown

Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Malignant Melanoma Stage IV

Germany
Herlev Hospital

Active, not recruiting

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac)

Non Small Cell Lung Cancer Metastatic | Malignant Melanoma, Metastatic | Bladder Urothelial Carcinoma, Metastatic

Denmark
National Cancer Institute, Naples

Completed

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma (SICOG 0109)

Recurrent Melanoma | Malignant Melanoma
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
Baylor Research Institute

Terminated

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

Malignant Melanoma Stage IV

United States
Prof. Dr. med. Dirk Schadendorf
Boehringer Ingelheim; medac GmbH; Alcedis GmbH

Completed

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma (NIPAWILMA)

Cutaneous Malignant Melanoma

Germany
Viralytics

Completed

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) (CALM)

Malignant Melanoma

United States
Ruhr University of Bochum

Completed

Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

Malignant Melanoma | Naevi

Germany
University Hospital Tuebingen

Completed

NAM-Trial: Multiferon in Malignant Melanoma

Locoregional Metastases in Malignant Melanoma Stages IIIB/C

Germany
St. Louis University

Completed

Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel)

Melanoma | Metastatic Melanoma | Stage IV Melanoma | Unresectable Malignant Neoplasm | Stage III Melanoma

United States
Sheba Medical Center

Recruiting

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Malignant Melanoma Stage IV

Israel
Baylor Research Institute

Completed

Combined Modality Treatment for Patients With Stage IV Melanoma

Malignant Melanoma Stage IV

United States
Jonsson Comprehensive Cancer Center
GlaxoSmithKline; Tesaro, Inc.

Completed

PET Imaging of the Immune System Using Analog Probes

Malignant Melanoma

United States
University Hospital Tuebingen

Terminated

Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC (NEO-VC)

Malignant Melanoma

Germany, France
Philogen S.p.A.

Completed

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Malignant Melanoma

Austria, Germany
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC; Celgene

Active, not recruiting

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Metastatic Melanoma | Melanoma and Other Malignant Neoplasms of Skin

United States
Scancell Ltd

Recruiting

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Melanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage III

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
Accuray Incorporated

Completed

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Stage IV Skin Melanoma | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Spine

United States
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Malignant Melanoma

Portugal
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study

Malignant Melanoma

China

Clinical Trials on Malignant Melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations